Robert Dorkin
About Robert Dorkin
Robert Nelsen Board Director and Co-founder of ARCH Venture Partners
Robert Nelsen holds the role of Board Director and is the Co-founder and Managing Director at ARCH Venture Partners. With his extensive expertise, Nelsen has been instrumental in the creation, early sourcing, financing, and development of over 150 companies. His notable early stage investments include influential companies such as Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Beam Therapeutics, and Karuna Therapeutics. These achievements highlight Nelsen’s pivotal role in the venture capital sector, particularly in biotechnology.
Robert Nelsen Education Background
Robert Nelsen earned an M.B.A. from the University of Chicago. Prior to his M.B.A., he completed his undergraduate studies at the University of Puget Sound, where he majored in economics and biology. This diverse educational background provided Nelsen with a solid foundation that has aided his venture capital and biotechnology career.
Robert Nelsen Directorships in Biotechnology Companies
Robert Nelsen serves as a director of several prominent biotechnology companies. His leadership roles include directorships at Vir Biotechnology, Sana Biotechnology, Lyell Immunopharma, National Resilience, Insitro, Prime Medicine, Nutcracker Therapeutics, Neumora Therapeutics, and Brii Biosciences. Additionally, Nelsen is the chairman of Hua Medicine. His involvement in these companies underscores his significant impact on the biotechnology industry.
Robert Nelsen's Past Roles and Affiliations
Robert Nelsen has previously served in several influential roles. He was a Trustee at the Fred Hutchinson Cancer Research Institute and the Institute of Systems Biology. He also held a position as a Director of the National Venture Capital Association. These roles reflect his extensive experience and deep connections within both the venture capital and scientific research communities.